

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6657166

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HVIVO SERVICES LIMITED	04/13/2021
RECEIVING PARTY DATA		
Name:	ORPH PHARMA IP COMPANY LIMITED	
Street Address:	QUEEN MARY BIOENTERPRISES INNOVATION CENTRE	
Internal Address:	42 NEW ROAD	
City:	LONDON	
State/Country:	ENGLAND	
Postal Code:	E1 2AX	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	9833506
CORRESPONDENCE DATA		
Fax Number:	(212)588-0500	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(212) 588-0800	
Email:	Docket@haugpartners.com	
Correspondent Name:	HAUG PARTNERS LLP	
Address Line 1:	745 FIFTH AVENUE	
Address Line 2:	10TH FLOOR	
Address Line 4:	NEW YORK, NEW YORK 10151	
ATTORNEY DOCKET NUMBER:	A488-1000	
NAME OF SUBMITTER:	JON GORDON	
SIGNATURE:	/Jon Gordon/	
DATE SIGNED:	04/14/2021	
Total Attachments: 2		
source=ASN#page1.tif		
source=ASN#page2.tif		

ASSIGNMENT

hVIVO Services Limited, incorporated and registered in England and Wales with company number 02326557 and having a registered office at Queen Mary Bioenterprises Innovation Centre, 42 New Road, London, E1 2AX (referred to, together with its successors and assigns, as “hVIVO”) owns U.S. Patent 9,833,506, titled “Vaccine - Screening Method” and issued on 5 December 2017 (referred to as “the Patent”).

hVIVO wishes to transfer all right, title, and interest in and to the Patent to Orph Pharma IP Company Limited, incorporated and registered in England and Wales with company number 13279216 and having a registered office at Queen Mary Bioenterprises Innovation Centre, 42 New Road, London, E1 2AX (referred to, together with its successors and assigns, as “Orph”).

ORPH desires to acquire all right, title, and interest in and to the Patent from hVIVO.

hVIVO and ORPH therefore agree that:

(1) **Assignment.** For the sum of ten dollars and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, hVIVO hereby assigns and sells to Orph all of hVIVO’s right, title and interest in and to the Patent throughout the world. This assignment includes, without limitation, all files, documentation, records, specifications, emails, letters, diagrams, spreadsheets, and the like relating to the Patent; all rights to claim the priority date of the Patent under United States law, the Patent Cooperation Treaty and/or other international arrangements of any earlier United States or other applications; all rights to sue, to bring any cause of action, and to enforce, including all rights to recover damages, injunctive relief and other remedies for past, present, and future infringements of any of the foregoing; all rights to collect royalties and other payments under or on account of the Patent; any and all other rights and interests arising out of, in connection with, or in relation to the Patent and/or all inventions that the Patent discloses; the same to be held and enjoyed by Orph entirely as if the same would have been held and enjoyed by hVIVO had this sale and assignment not been made.

(2) **Miscellaneous.** If any part of this Assignment shall be held by a court of competent jurisdiction to be void, invalid, or inoperative, the remaining provisions of this Assignment shall not be affected and shall continue in effect, and the invalid provision shall be deemed modified to the least degree necessary to remedy such invalidity.

In testimony whereof, hVIVO has executed and delivered this Assignment on the date indicated below.

hVIVO:

Effective Date: 13 April 2021

hVIVO Services Limited

By: 

Name: Leo Toole

Title: Director

Acknowledged and Agreed:

Orph:

Orph Pharma IP Company Limited

By: 

Name: Cathal Friel

Title: Director

(The remainder of this page is blank.)